Show simple item record

dc.contributor.authorMontalvo Quiros, Sandra
dc.contributor.authorVallet Regí, María
dc.contributor.authorPalacios, Ainhoa
dc.contributor.authorAnguita, Juan
dc.contributor.authorPrados Rosales, Rafael
dc.contributor.authorGonzález, Blanca
dc.contributor.authorLuque García, José L.
dc.date.accessioned2021-07-27T11:31:43Z
dc.date.available2021-07-27T11:31:43Z
dc.date.issued2020
dc.identifier.issn1999-4923spa
dc.identifier.urihttp://hdl.handle.net/10641/2369
dc.description.abstractThe increasing emergence of new strains of Mycobacterium tuberculosis (Mtb) highly resistant to antibiotics constitute a public health issue, since tuberculosis still constitutes the primary cause of death in the world due to bacterial infection. Mtb has been shown to produce membrane-derived extracellular vesicles (EVs) containing proteins responsible for modulating the pathological immune response after infection. These natural vesicles were considered a promising alternative to the development of novel vaccines. However, their use was compromised by the observed lack of reproducibility between preparations. In this work, with the aim of developing nanosystems mimicking the extracellular vesicles produced by Mtb, mesoporous silica nanoparticles (MSNs) have been used as nanocarriers of immunomodulatory and vesicle-associated proteins (Ag85B, LprG and LprA). These novel nanosystems have been designed and extensively characterized, demonstrating the e ectiveness of the covalent anchorage of the immunomodulatory proteins to the surface of the MSNs. The immunostimulatory capacity of the designed nanosystems has been demonstrated by measuring the levels of pro- (TNF) and anti-inflammatory (IL-10) cytokines in exposed macrophages. These results open a new possibility for the development of more complex nanosystems, including additional vesicle components or even antitubercular drugs, thus allowing for the combination of immunomodulatory and bactericidal e ects against Mtb.spa
dc.language.isoengspa
dc.publisherPharmaceuticsspa
dc.rightsAtribución-NoComercial-SinDerivadas 3.0 España*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es/*
dc.subjectMycobacterium tuberculosisspa
dc.subjectMesoporous silica nanoparticlesspa
dc.subjectImmunomodulatory proteinsspa
dc.subjectImmune system activationspa
dc.subjectTuberculosis vaccinesspa
dc.titleMesoporous Silica Nanoparticles as a Potential Platform for Vaccine Development against Tuberculosis.spa
dc.typearticlespa
dc.description.versionpost-printspa
dc.rights.accessRightsopenAccessspa
dc.description.extent2418 KBspa
dc.identifier.doi10.3390/pharmaceutics12121218spa
dc.relation.publisherversionhttps://www.mdpi.com/1999-4923/12/12/1218spa


Files in this item

FilesSizeFormatView
2.- Mesoporous Silica Nanoparticles ...2.360MbPDFView/Open

This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial-SinDerivadas 3.0 España
Except where otherwise noted, this item's license is described as Atribución-NoComercial-SinDerivadas 3.0 España